---
document_datetime: 2024-07-26 13:33:00
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lenalidomide-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.8752578
conversion_datetime: 2026-01-10 11:41:07.219408
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lenalidomide Krka

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0007/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 02/07/2024                          |                                             | SmPC and Annex II                |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                      |            |            |                        |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/1838/ 202212 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31/08/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0006/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/06/2023 | 17/07/2023 | SmPC and PL            |                                   |
| IB/0004            | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                               | 15/12/2021 | 18/07/2022 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0003   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                  | 11/10/2021   | 18/07/2022   | SmPC                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| IAIN/0002 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                            | 04/08/2021   | 18/07/2022   | SmPC, Annex II, Labelling and PL |
| IA/0001   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 07/05/2021   | n/a          |                                  |